title: [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
abstract: Prospective, randomized, multicenter study in 267 patients with complicated urinary infection from 9 hospitals nationwide. Drug treatment was either Ceftriaxone 1 g once daily parenterally or Cefotaxime parenteral 1 g 8 hourly for a minimum of 7 days. Patients were clinically, analytically and microbiologically evaluated before and after treatment to assess the efficacy and tolerance of both drug products. To evaluate treatment cost, we used the price of both drugs and the material required for their administration (syringe and disposable needle). 119 patients were excluded from the cost-efficacy evaluation and 148 remained in the study (75 assigned to treatment with Ceftriaxone and 73 to Cefotaxime). Clinical efficacy of treatment was 93% and 87.6% for Ceftriaxone and Cefotaxime respectively (p > 0.05). Cost per patient was 27,347 pesetas for Ceftriaxone and 34,490 for Cefotaxime (p < 0.05).
authors.affiliation: Servicio de Urología, Hospital Universitario La Fe., Valencia.
authors.forename: J M
authors.initials: JM
authors.lastname: Martínez Jabaloyas
authors.forename: S
authors.initials: S
authors.lastname: Sanz Chinesta
authors.forename: J F
authors.initials: JF
authors.lastname: Jiménez Cruz
authors.forename: N
authors.initials: N
authors.lastname: Flores Corral
authors.forename: M
authors.initials: M
authors.lastname: Unda Urzaiz
authors.forename: O
authors.initials: O
authors.lastname: Leiva Galvis
authors.forename: V
authors.initials: V
authors.lastname: González Romojaro
authors.forename: C
authors.initials: C
authors.lastname: Hernández Fernández
authors.forename: E
authors.initials: E
authors.lastname: Lledó García
authors.forename: L A
authors.initials: LA
authors.lastname: Rioja Sanz
authors.forename: A
authors.initials: A
authors.lastname: Gonzalvo Ibarra
authors.forename: J E
authors.initials: JE
authors.lastname: Camacho González
authors.forename: F
authors.initials: F
authors.lastname: Ruíz Alvárez-Cienfuegos
authors.forename: L
authors.initials: L
authors.lastname: Resel Estévez
authors.forename: J
authors.initials: J
authors.lastname: Corral Saleta
authors.forename: R
authors.initials: R
authors.lastname: Burgos Rodríguez
authors.forename: J M
authors.initials: JM
authors.lastname: Del Rosal Samaniego
mesh_terms: D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000191:economics* / Q000627:therapeutic use*; D002443:Ceftriaxone / Q000191:economics* / Q000627:therapeutic use*; D002511:Cephalosporins / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014552:Urinary Tract Infections / Q000188:drug therapy*
chemical_list: D002511:Cephalosporins; D002443:Ceftriaxone; D002439:Cefotaxime